Comparison of the antidiabetic effects of linagliptin among groups with a normal renal function and a mild or severe renal impairment - Retrospective observation study of Japanese patients with type 2 diabetes mellitus

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 3, 2015, Pages 289-296

  Ito, Hiroyuki ^a   Abe, Mariko ^a   Antoku, Shinichi ^a   Omoto, Takashi ^a   Shinozaki, Masahiro ^a   Nishio, Shinya ^a   Mifune, Mizuo ^a   Togane, Michiko ^a  

^a 2 24 18 Higashikoiwa   (Japan)

Author keywords

Adherence; Antiproteinuric effect; Dipeptidyl peptidase 4 inhibitor; Linagliptin; Renal impairment; Type 2 diabetes mellitus

Indexed keywords

HEMOGLOBIN A1C; LINAGLIPTIN; ANTIDIABETIC AGENT; PURINE DERIVATIVE; QUINAZOLINE DERIVATIVE;

AGED; ARTICLE; CHOLECYSTITIS; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG FATALITY; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; JAPANESE (PEOPLE); KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MILD RENAL IMPAIRMENT; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PNEUMONIA; RETROSPECTIVE STUDY; SEVERE RENAL IMPAIRMENT; SUDDEN DEATH; TREATMENT OUTCOME; VERTIGO; ASIAN CONTINENTAL ANCESTRY GROUP; CASE CONTROL STUDY; COMPARATIVE STUDY; COMPLICATION; DIABETES MELLITUS, TYPE 2; KIDNEY FAILURE; PATHOPHYSIOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; PURINES; QUINAZOLINES; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES;

EID: 84921442873     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.995091     Document Type: Article

References (27)

1. Ito H, Oshikiri K, Mifune M, et al. The usefulness of the revised classification for chronic kidney disease by the KDIGO for determining the frequency of diabetic micro- and macroangiopathies in Japanese patients with type 2 diabetes mellitus. J Diabetes Complications 2012;26:286-90
2. Ito H, Antoku S, Furusho M, et al. The prevalence of the risk factors for atherosclerosis among type 2 diabetic patients is greater in the progressive stages of chronic kidney disease. Nephron Extra 2013;3:66-72
3. Wasén E, Isoaho R, Mattila K, et al. Renal impairment associated with diabetes in the elderly. Diabetes Care 2004;27:2648-53
4. Kurella Tamura M, Xie D, Yaffe K, et al. Vascular risk factors and cognitive impairment in chronic kidney disease: the chronic renal insufficiency cohort (CRIC) study. Clin J Am Soc Nephrol 2011;6:248-56
5. Elias MF, Dore GA, Davey A. Kidney disease and cognitive function. Contrib Nephrol 2013;179:42-57
6. Haneda M, Morikawa A. Which hypoglycaemic agents to use in type 2 diabetic subjects with CKD and how? Nephrol Dial Transplant 2009;24:338-41
7. Arjona Ferreira JC, Marre M, Barzilai N, et al. Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency. Diabetes Care 2013;36:1067-73
8. Arjona Ferreira JC, Corry D, Mogensen CE, et al. Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-Week Randomized Trial. Am J Kidney Dis 2013;61:579-87
9. Lukashevich V, Schweizer A, Shao Q, et al. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab 2011;13:947-54
10. Ito H, Mifune M, Matsuyama E, et al. Vildagliptin is effective for glycemic control in diabetic patients undergoing either hemodialysis or peritoneal dialysis. Diabetes Ther 2013;4:321-9
11. Fujii Y, Abe M, Higuchi T, et al. The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Expert Opin Pharmacother 2013;14:259-67
12. Nowicki M, Rychlik I, Haller H, D1680C00007 Investigators. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes Metab 2011;13:523-32
13. Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 2011;13:7-18
14. Scheen AJ. Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes. Clin Pharmacokinet 2014. [Epub ahead of print]
15. Deacon CF, Holst JJ. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. Expert Opin Investig Drugs 2010;19:133-40
16. Graefe-Mody U, Friedrich C, Port A, et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 2011;13:939-46
17. McGill JB, Sloan L, Newman J, et al. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care 2013;36:237-44
18. McGill JB, Barnett AH, Lewin AJ, et al. Linagliptin added to sulphonylurea in uncontrolled type 2 diabetes patients with moderate-to-severe renal impairment. Diab Vasc Dis Res 2014;11:34-40
19. Groop PH, Cooper ME, Perkovic V, et al. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care 2013;36:3460-8
20. Kidney disease: improving global outcomes (KDIGO) CKD Work Group. KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3:1-150
21. Matsuo S, Imai E, Horio M, et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009;53:982-92
22. Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: third national health and nutrition examination survey. Am J Kidney Dis 2003;41:1-12
23. National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis 2012;60:850-86
24. Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA consensus conference. Diabetes Care 2014;37:2864-83
25. DeFronzo RA, Stonehouse AH, Han J, Wintle ME. Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabet Med 2010;27:309-17
26. Monami M, Lamanna C, Desideri CM, Mannucci E. DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther 2012;29:14-25
27. Monami M, Vitale V, Ambrosio ML, et al. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials. Adv Ther 2012;29:736-46